FAS and breast cancer: Furthermore, the combination of butyrate with tumor necrosis factor-α (TNF-α), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and anti-Fas agonist has been found to strongly induce apoptosis, leading to a significant decrease in the viability of breast cancer cells [106].